Lenvatinib versus sorafenib in first‐line treatment of unresectable hepatocellular carcinoma: An inverse probability of treatment weighting analysis

Abstract

Present results confirmed randomized controlled trial in the real-life setting, but also suggests that in earlier stages some benefit can be expected.